From pipeline to patient: New developments in cystic fibrosis therapeutics

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 3, 2013, Pages 323-329

  Prayle, Andrew P ^a   Smyth, Alan R ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Aerosolised antibiotics; CFTR modulation; Cystic fibrosis; New therapies

Indexed keywords

AMIKACIN; ATALUREN; AZITHROMYCIN; AZTREONAM; CHLORIDE CHANNEL STIMULATING AGENT; CIPROFLOXACIN; COLISTIMETHATE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DENUSOFOL; FOSFOMYCIN; GROWTH HORMONE; INSULIN; ISOPRENALINE; IVACAFTOR; LEVOFLOXACIN; LIPROTAMASE; LUMACAFTOR; MANNITOL; MIGLUSTAT; PLACEBO; RISEDRONIC ACID; TOBRAMYCIN; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANTIBIOTIC THERAPY; BONE PAIN; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; ENZYME REPLACEMENT; FORCED EXPIRATORY VOLUME; GAUCHER DISEASE; HUMAN; INFECTION; INSULIN TREATMENT; MULTIPLE CYCLE TREATMENT; MYALGIA; NASAL POTENTIAL DIFFERENCE; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CYSTIC FIBROSIS; DRUG DESIGN; HUMANS;

EID: 84873398616     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.769958     Document Type: Review

References (37)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373(9678):1891- 904
2. CF Trust. UK CF registry annual data report 2010. CF Trust, Bromley, UK; 2010
3. Dodge JA, Lewis PA, Stanton M, et al. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29(3):522-6 (Pubitemid 46372100)
4. Frerichs C, Smyth A. Treatment strategies for cystic fibrosis: What's in the pipelinë Expert Opin Pharmacother 2009;10(7):1191-202
5. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012;487(7405):109-13
6. Corey M. Power considerations for studies of lung function in cystic fibrosis. Proc Am Thorac Soc 2007;4(4):334-7 (Pubitemid 47330866)
7. Schuler D, Sermet-Gaudelus I, Wilschanski M, et al. Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 2004;3(SUPPL2):151-5 (Pubitemid 40045589)
8. Durmowicz AG, Witzmann KA, Rosebraugh CJ, et al. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: The ivacaftor experience. Chest 2013;143(1):14-18
9. Mott LS, Park J, Murray CP, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012;67(6):509-16
10. Thomas KE, Parnell-Parmley JE, Haidar S, et al. Assessment of radiation dose awareness among pediatricians. Pediatr Radiol 2006;36(8):823-32 (Pubitemid 44138277)
11. O'Connell OJ, McWilliams S, McGarrigle A, et al. Radiologic imaging in cystic fibrosis: Cumulative effective dose and changing trends over 2 decades. Chest 2012;141(6):1575-83
12. Fuchs SI, GappaM. Lung clearance index: Clinical and research applications in children. Paediatr Respir Rev 2011;12(4):264-70
13. Aurora P, Stanojevic S, Wade A, et al. Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2011;183(6):752-8
14. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011;10(1):54-61
15. Schuster A, Haliburn C, Doring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: A randomised study. Thorax 2012; doi:10.1136/thoraxjnl-2012-202059
16. Dupont L, Minic P, Fustic S, et al. A randomized placebo-Controlled study of nebulized liposomal amikacin (Arikace (TM)) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Cystic Fibrosis 2008;7(SUPPL2):S26-6
17. Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53(9):3847-54
18. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183(11):1510-16
19. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012;185(2):171-8
20. Stick SM, Sly PD. Exciting new clinical trials in cystic fibrosis: Infants need not apply. Am J Respir Crit Care Med 2011;183(12):1577-8
21. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139(3):359-65 (Pubitemid 32889511)
22. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: An efficacy and safety study. Eur Respir J 2011;38(5):1071-80
23. Aitken ML, Bellon G, De Boeck K, et al. Long-Term inhaled dry powder mannitol in cystic fibrosis: An international randomized study. Am J Respir Crit Care Med 2012;185(6):645-52
24. Accurso FJ, Moss RB, Wilmott RW, et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011;183(5):627-34
25. Ratjen F, Durham T, Navratil T, et al. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 2012;11(6):539-49
26. Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011;38(1):59-69
27. Rowe S, Sermet-Gaudelus I, Konstan MW, et al. Results of the phase 3 study of ataluren in nonsense mutation cystic fibrosis (NMCF) [abstract]. Pediatric Pulmonology 2012;47(SUPPL35):290
28. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663-72
29. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142(3):718-24
30. Boyle MP, Bell S, Konstan M, et al. The investigational CFTR corrector, VX809 (lumacaftor) co-Administered with the oral potentiator ivacaftor improved CFTR and lung function in F508DEL homozygous patients: Phase II study results. Pediatric Pulmonology 2012 ;47(Supplt 35):315
31. Norez C, Noel S, Wilke M, et al. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006;580(8):2081-6
32. Leonard A, Lebecque P, Dingemanse J, et al. A randomized placebo-Controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros 2012;11(3):231-6
33. Minicucci L, HauPTM, Casciaro R, et al. Slow-release insulin in cystic fibrosis patients with glucose intolerance: A randomized clinical trial. Pediatr Diabetes 2012;13(2):197-202
34. Stalvey MS, Anbar RD, Konstan MW, et al. A multi-Center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatr Pulmonol 2012;47(3):252-63
35. Haworth CS, Sharples L, Hughes V, et al. Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. J Cyst Fibros 2011;10(6):470-6
36. Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 2012;4:CD002010
37. Borowitz D, Stevens C, Brettman LR, et al. International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros 2011;10(6):443-52